Oregon Psilocybin Services One Year In: What We've Learned
Oregon's Measure 109, passed in 2020, created the first regulated psilocybin services program in the United States. After years of rulemaking by the Oregon Health Authority (OHA), the program began licensing service centers and facilitators in 2023. As the program moves past its first full year of operation, enough data and first-hand accounts have accumulated to draw some meaningful conclusions — and identify significant challenges that remain.
What the Program Actually Is
Oregon's psilocybin services framework is deliberately narrow. It is not a medical treatment program, and it is not decriminalization. It is a supervised wellness services model.
Key features:
- Adults 21 and over can access psilocybin sessions at licensed service centers
- Sessions must be administered by a licensed psilocybin facilitator
- No prescription or medical diagnosis is required
- Psilocybin cannot be purchased for home use
- Facilitators must complete an approved training program and pass state licensing requirements
- Service centers must meet facility and safety standards set by OHA
The program intentionally avoids medical framing to sidestep federal Controlled Substances Act issues. Psilocybin remains federally illegal; Oregon's program operates under state law.
Where Things Stand: Licensed Providers
By late 2025, Oregon had licensed approximately 300 facilitators and roughly 30 service centers operating across the state. The geographic distribution is heavily skewed toward the Portland metro area and a few other urban centers. Rural Oregon — which covers the majority of the state's landmass — has very limited access.
Service centers range from clinical-adjacent settings that emphasize therapy-informed preparation and integration, to more retreat-style or ceremonial settings. The diversity of models reflects the broad flexibility OHA built into the program.
Waitlists at most established service centers are substantial — several months at many providers. Demand has consistently outpaced licensed capacity, particularly in the first year.
Access and Cost: The Persistent Challenge
Cost remains the most significant barrier to access. A full Oregon psilocybin session — including preparation meeting, the session itself (typically 6-8 hours), and integration support — runs $1,500 to $3,500 depending on the provider. This is entirely out-of-pocket: no health insurance covers Oregon psilocybin services, and federal illegality makes insurance coverage legally complex.
The program has no provision for income-based sliding scale fees or state-funded access for low-income Oregonians, though some individual providers offer reduced rates. Advocacy groups and researchers have noted that this creates a program that is structurally accessible primarily to upper-middle-class and wealthy participants — the opposite of equity-centered healthcare.
The Oregon Psilocybin Advisory Board has discussed access and equity extensively but has not yet produced a funding mechanism for subsidized access. Several service centers have created independent scholarship funds, which cover a small number of clients.
What's Working
Safety record: Oregon has not reported serious adverse events attributable to psilocybin in licensed sessions. No hospitalizations, no deaths. This is consistent with psilocybin's strong safety profile in clinical trials.
Facilitator quality: The training and licensing requirements, which some in the industry initially criticized as too burdensome, appear to have produced a facilitator cohort that takes harm reduction seriously. Preparation meetings — required before every session — allow facilitators to screen for contraindications and set appropriate expectations.
Diverse models: The flexibility of the Oregon framework has allowed ceremonial, therapeutic, and wellness-oriented approaches to coexist. This is a feature, not a bug: it acknowledges that different clients have different needs and value different frameworks.
Real-world evidence generation: Oregon's program is producing observational data that complements clinical trials. Oregon Health & Science University and other researchers have established research partnerships with service centers to track outcomes, adverse events, and client characteristics. This real-world evidence will be valuable as other states and eventually the federal government considers regulatory frameworks.
What Needs Improvement
Geographic equity: The concentration of service centers in Portland is a serious limitation. Oregonians in rural counties face travel burdens that effectively exclude them.
Cost and economic access: Without insurance coverage or a subsidized access program, the client base skews heavily toward those who can afford $1,500+ out of pocket.
Data transparency: OHA collects relatively limited data from licensed providers, and what is collected is not consistently published in accessible formats. More systematic outcome tracking would benefit both policy and public understanding.
Integration support: Preparation is required; integration is not. Many facilitators offer integration sessions as an add-on, but there is no requirement that clients receive post-session support. Given the importance of integration to therapeutic outcomes, this is a gap.
Lessons for Other States
Colorado passed Proposition 122 in 2022, creating a regulated access program that will launch its first licensed centers in 2025-2026. Other states are watching Oregon closely.
The clearest lesson from Oregon year one is that regulated psilocybin access is feasible — the sky did not fall, and the safety record is strong. The harder lesson is that market-based access without equity provisions defaults to serving wealthy early adopters. States that design programs without explicit equity mechanisms will likely reproduce Oregon's access gaps.
What Comes Next
OHA continues to refine rules based on first-year experience. Key questions under active consideration include: whether telehealth preparation and integration sessions can be licensed (which would reduce cost), whether group session models can be further expanded, and how to address rural access gaps.
Oregon's program is a genuine policy experiment. It is producing real-world evidence that will shape psilocybin regulation for years. The first year's lesson is that the model works, but "works" and "works equitably" are not the same thing.